Mostrar el registro sencillo del ítem
| dc.creator | Bertrán, X. | |
| dc.creator | Mañé Almero, Josep | |
| dc.creator | Fernández Bañares, Fernando | |
| dc.creator | Castellà, E. | |
| dc.creator | Bartolí, R. | |
| dc.creator | Ojanguren Sabán, Isabel | |
| dc.creator | Esteve i Comas, Maria | |
| dc.creator | Gassull, Miquel Àngel | |
| dc.date | 2011-07-07T12:30:33Z | |
| dc.date | 2011-07-07T12:30:33Z | |
| dc.date | 1996 | |
| dc.date.accessioned | 2024-12-16T10:27:15Z | |
| dc.date.available | 2024-12-16T10:27:15Z | |
| dc.identifier | 0017-5749 | |
| dc.identifier | http://hdl.handle.net/2445/18658 | |
| dc.identifier | 160920 | |
| dc.identifier | 8984030 | |
| dc.identifier.uri | http://fima-docencia.ub.edu:8080/xmlui/handle/123456789/22138 | |
| dc.description | BACKGROUND: 5-Lipoxygenase products play a part in inflammatory response. AIMS: The effect of intracolonic administration of zileuton (a 5-lipoxygenase inhibitor) on colonic damage and eicosanoid local release was assessed in a rat model of colitis. METHODS: Ninety rats with trinitrobenzenesulphonic acid induced colitis were randomised to receive placebo, 5-aminosalicylic acid (50 mg/kg), or zileuton (50 mg/kg) intracolonically for four weeks. Local eicosanoid release was monitored by intracolonic dialysis throughout the study. The colon was removed for macroscopic and histological assessment at weeks 1, 2, and 4 after colitis induction in 10 rats of each group. RESULTS: Zileuton significantly reduced macroscopic damage score after four weeks of treatment in comparison with the other two groups (p = 0.034). In addition, zileuton administration significantly increased the intracolonic release of both thromboxane B2 at week 1 (p = 0.05) and prostaglandin E2 at weeks 2 and 4 (p < 0.05). Zileuton and 5-aminosalicylic acid decreased leukotriene B4 release by 90% at day 3. CONCLUSIONS: Intracolonic zileuton, compared with 5-aminosalicylic acid and placebo, seems to improve the course of the disease in a model of chronic colitis. This effect may be related to an increased and maintained production of prostaglandin E2 together with inhibition of leukotriene B4 synthesis. | |
| dc.format | 6 p. | |
| dc.format | application/pdf | |
| dc.language | eng | |
| dc.publisher | BMJ Group | |
| dc.relation | Reproducció digital del document publicat a: http://dx.doi.org/10.1136/gut.38.6.899 | |
| dc.relation | Gut, 1996, vol. 38, núm. 6, p. 899-904 | |
| dc.relation | http://dx.doi.org/10.1136/gut.38.6.899 | |
| dc.rights | (c) BMJ Publishing Group Ltd and British Society of Gastroenterology, 1996 | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.source | Articles publicats en revistes (Medicina) | |
| dc.subject | Colitis | |
| dc.subject | Còlon | |
| dc.subject | Antienzims | |
| dc.subject | Terapèutica | |
| dc.subject | Colitis | |
| dc.subject | Colon | |
| dc.subject | Enzyme inhibitors | |
| dc.subject | Therapeutics | |
| dc.title | Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion |
| Ficheros | Tamaño | Formato | Ver |
|---|---|---|---|
|
No hay ficheros asociados a este ítem. |
|||